iTeos Therapeutics, Inc.

Equities

ITOS

US46565G1040

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:01 2024-03-28 pm EDT 5-day change 1st Jan Change
13.64 USD +3.57% Intraday chart for iTeos Therapeutics, Inc. +19.65% +24.57%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Top Premarket Decliners MT
JPMorgan Adjusts Price Target on iTeos Therapeutics to $27 From $29, Maintains Overweight Rating MT
Wedbush Adjusts iTeos Therapeutics Price Target to $18 From $25, Maintains Outperform Rating MT
ITeos Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
ITeos Therapeutics, Inc. Appoints Jill DeSimone to its Board of Directors, Effective March 7, 2024 CI
Transcript : ITeos Therapeutics, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 03:00 PM
Iteos Therapeutics, Inc. Announces Business Updates and Strategic Priorities for 2024 CI
ITeos Therapeutics, Inc.(NasdaqGM:ITOS) dropped from S&P Biotechnology Select Industry Index CI
Iteos Therapeutics, Inc. Announces Board Changes CI
JPMorgan Cuts Price Target on iTeos Therapeutics to $29 From $32, Maintains Overweight Rating MT
ITeos Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
ITeos Therapeutics, Inc.(NasdaqGM:ITOS) dropped from S&P 1000 CI
ITeos Therapeutics, Inc.(NasdaqGM:ITOS) dropped from S&P 600 Health Care CI
ITeos Therapeutics, Inc.(NasdaqGM:ITOS) dropped from S&P Composite 1500 CI
ITeos Therapeutics, Inc.(NasdaqGM:ITOS) dropped from S&P 600 CI
NCR Atleos to Join S&P SmallCap 600 Index, Replacing iTeos Therapeutics MT
NCR Atleos to Join S&P SmallCap 600 Index, Replacing iTeos Therapeutics MT
Sector Update: Health Care Stocks Rising Late Afternoon MT
Sector Update: Health Care Stocks Gaining in Afternoon Trading MT
Top Midday Gainers MT
Arcus Biosciences, iTeos Therapeutics Shares Rise After Roche's Positive Lung Cancer Interim Results MT
Top Premarket Gainers MT
ITeos Therapeutics Shares Surge More Than 21% in Premarket Activity Wednesday MT
HC Wainwright Adjusts Price Target on iTeos Therapeutics to $44 From $54, Maintains Buy Rating MT
ITeos Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Chart iTeos Therapeutics, Inc.
More charts
iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes three clinical-stage programs targeting novel, validated immuno-oncology pathways. Its lead antibody product candidate, belrestotug, also known as EOS-448/GSK4428859A, is an antagonist of TIGIT, an immune checkpoint with multiple mechanisms of action. Its advanced program is inupadenant, also known as EOS-850, a next-generation adenosine 2A receptor (A2AR) antagonist tailored to overcome the specific adenosine-mediated immunosuppression found in the tumor microenvironment. Its program to initiate clinical trials is EOS-984, a potentially first-in-class small molecule focused on a new mechanism in the adenosine pathway by targeting equilibrative nucleoside transporter 1 (ENT1), a dominant transporter of adenosine on lymphocytes involved in T cell metabolism.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
13.64 USD
Average target price
34.4 USD
Spread / Average Target
+152.20%
Consensus